Skip to main content
. 2021 Jul 6;54(4):402–411. doi: 10.1111/apt.16477

TABLE 1.

Demographic characteristics (full‐analysis set)

Demographics Tegoprazan Placebo
50 mg (n = 106) 100 mg (n = 99) (n = 99)
Age (years) 45.4 (12.2) 44.1 (13.3) 45.6 (13.3)
Male (%) 31 (29.3) 37 (37.4) 31 (31.3)
Height (cm) 163.5 (8.8) 164.4 (8.4) 163.9 (8.2)
Weight (kg) 61.3 (10.8) 63.3 (11.8) 62.7 (12.1)
Body mass index (kg/m2) 22.9 (3.2) 23.3 (3.4) 23.2 (3.0)
≥25 and ≤30, n (%) 22 (20.8) 20 (20.2) 27 (27.3)
>30, n (%) 2 (1.9) 4 (4.0) 1 (1.0)
Smoking, n (%) 12 (11.3) 19 (19.2) 11 (11.1)
Alcohol consumption, n (%) 33 (31.1) 39 (39.4) 33 (33.3)

Values are presented as mean (standard deviation) except for gender, smoking, and alcohol consumption, which were presented as mean (%).

Abbreviation: n, number of patients.